sabatolimab

Roche takes the Tim-3 battle to Novartis
EP Vantage
Thu, 07/22/21 - 10:53 am
Roche
sabatolimab
Novartis
RG7769
bispecific antibodies
Key third-quarter readouts for big pharma
EP Vantage
Tue, 06/29/21 - 10:59 am
clinical trials
Pfizer
Roche
idanacogene elaparvovec
Alexion
AstraZeneca
Ultomiris
AbbVie
Rinvoq
Novartis
sabatolimab